We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+4.45%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$332M
(+20%)
Cap. Flow
+$245M
Cap. Flow
% of AUM
12.29%
Top 10 Holdings %
Top 10 Hldgs %
47.04%
Holding
78
New
21
Increased
16
Reduced
12
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$91M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$72.3M |
| 3 |
Agilent Technologies
A
|
+$56.1M |
| 4 |
Intuitive Surgical
ISRG
|
+$52.5M |
| 5 |
Danaher
DHR
|
+$50.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International plc
ENDP
|
+$52.2M |
| 2 |
Viatris
VTRS
|
+$43M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$32.9M |
| 4 |
Merck
MRK
|
+$32.4M |
| 5 |
Gilead Sciences
GILD
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.01% |
| 2 | Financials | 3.91% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Merck
MRK
$321B
| $33.8M | 1.69% |
611,927
-593,273
| -49% | -$32.4M |
|
|
HSP
27
PUT
DELISTED
HOSPIRA INC
HSP
| $30.8M | 1.55% |
+600,000
| New | +$28.5M |
|
28
Teleflex
TFX
$5.86B
| $26.4M | 1.32% |
+250,000
| New | +$26.2M |
|
29
Akebia Therapeutics
AKBA
$362M
| $25M | 1.25% |
+900,000
| New | +$21.7M |
|
30
Vertex Pharmaceuticals
VRTX
$122B
| $23.7M | 1.19% |
+250,000
| New | +$17.5M |
|
|
ARAV
31
DELISTED
Aravive, Inc. Common Stock
ARAV
| $18.2M | 0.91% |
+108,333
| New | +$18.7M |
|
|
AMRI
32
DELISTED
Albany Molecular Research Inc
AMRI
| $17.6M | 0.88% |
875,000
-25,000
| -3% | -$423K |
|
|
33
PUT
Gilead Sciences
GILD
$163B
| $16.6M | 0.83% |
+200,000
| New | +$15.6M |
|
|
AET
34
DELISTED
Aetna Inc
AET
| $16.2M | 0.81% |
+199,600
| New | +$15.1M |
|
|
RGLS
35
DELISTED
Regulus Therapeutics
RGLS
| $12.5M | 0.62% |
12,917
-208
| -2% | -$178K |
|
|
INFI
36
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $11.8M | 0.59% |
923,600
-126,400
| -12% | -$1.32M |
|
37
Brookdale Senior Living
BKD
$3.49B
| $10.8M | 0.54% |
325,000
-175,000
| -35% | -$5.69M |
|
|
DSCI
38
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $10.6M | 0.53% |
920,000
+620,000
| +207% | +$6.36M |
|
39
Puma Biotechnology
PBYI
$402M
| $10.6M | 0.53% |
+161,000
| New | +$11.4M |
|
40
PUT
Cencora
COR
$60.7B
| $10.5M | 0.53% |
+145,000
| New | +$9.93M |
|
|
ITMN
41
DELISTED
INTERMUNE INC
ITMN
| $10.5M | 0.53% |
+237,964
| New | +$8.76M |
|
|
ARIA
42
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $8.6M | 0.43% |
+1,350,000
| New | +$9.28M |
|
43
Acadia Pharmaceuticals
ACAD
$4.55B
| $4.89M | 0.25% |
216,500
-483,500
| -69% | -$10.1M |
|
|
VIRX
44
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.5M | 0.23% |
3,286
| – | – |
|
45
Biogen
BIIB
$30.7B
| $4.41M | 0.22% |
+14,000
| New | +$4.21M |
|
46
UnitedHealth
UNH
$383B
| $3.37M | 0.17% |
+41,200
| New | +$3.24M |
|
|
CSII
47
DELISTED
Cardiovascular Systems, Inc.
CSII
| $3.25M | 0.16% |
104,400
+21,400
| +26% | +$617K |
|
|
ELOS
48
DELISTED
Syneron Medical Ltd
ELOS
| $2.36M | 0.12% |
228,800
+107,300
| +88% | +$1.16M |
|
|
KYTH
49
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $2.06M | 0.1% |
+53,800
| New | +$1.88M |
|
50
Novavax
NVAX
$1.22B
| $1.85M | 0.09% |
20,000
-35,812
| -64% | -$3.15M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2014 Portfolio in Review
As of Q2 2014, HealthCor Management held 78 positions worth $1.99B, up 20% from $1.66B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management deployed $245M of net new capital in Q2 2014, opening 21 new positions and adding to 16 existing holdings. Its largest new stake was Intuitive Surgical: 1,189,800 shares worth $54.4M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 65% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Viatris, an estimated $43M trimmed.
- HealthCor Management's largest Q2 2014 buy was Intuitive Surgical: 1,189,800 shares worth $54.4M.
- HealthCor Management added most to Allergan plc in Q2 2014, an estimated $91M increase.
- HealthCor Management's biggest Q2 2014 reduction was Viatris, cutting an estimated $43M.
- HealthCor Management fully exited Endo International plc in Q2 2014, selling an estimated $52.2M.
- HealthCor Management's ten largest holdings make up 47% of its $1.99B portfolio in Q2 2014.
- HealthCor Management opened 21 new positions and closed 27 in Q2 2014.
- HealthCor Management's portfolio value rose 20% quarter-over-quarter to $1.99B.
Based on HealthCor Management's 13F filing for Q2 2014, filed 14 Aug 2014.